Several stocks saw significant gains on Thursday, with Ameresco receiving a bullish upgrade from Jefferies, Lithium Americas experiencing potential government interest, and Kodiak Sciences getting an analyst upgrade.

The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Xilio Therapeutics, Inc. (NASDAQ: XLO) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares climbed 80% to $1.5395. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers. Ontrak, Inc. (NASDAQ: OTRK) gained 55% to $0.9239. Binah Capital Group, Inc. (NASDAQ: BCG) gained 48% to $14.05 after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Allego N.V. (NASDAQ: ALLG) rose 32.8% to $1.7650. Akanda Corp. (NASDAQ: AKAN) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Destiny Tech100 Inc. (NASDAQ: DXYZ) rose 26% to $22.15. REX American Resources Corporation (NYSE: REX) gained 23.2% to $54.15 following upbeat earnings. Nutriband Inc. (NASDAQ: NTRB) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Summit Therapeutics Inc. (NASDAQ: ...

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38. Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power'   Leading and Lagging Sectors   Real estate shares jumped by 0.7% on Thursday. In trading on Thursday, information technology shares fell by 0.2%.   Top Headline   U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000.   Equities Trading UP   Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares shot up 435% to $24.91 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Shares of Xilio Therapeutics, Inc. (NASDAQ: XLO) got a boost, surging 154% to $1.62 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ:

Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.

Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.